Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 4:12:794054.
doi: 10.3389/fphar.2021.794054. eCollection 2021.

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers

Min Wu  1 , Hong Zhang  1 , Qianqian Li  1 , Hong Chen  1 , Min Fang  2 , Lizhi Yang  3 , Yanhua Ding  1
Affiliations

Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of the QX002N anti-IL-17 Monoclonal Antibody: A Phase I, Randomized, Double-Blind, Single Ascending Dose Study in Healthy Chinese Volunteers

Min Wu et al. Front Pharmacol. .

Abstract

Background: The innovative injection of interleukin 17 A (IL-17A) monoclonal antibody QX002N is being developed to treat active ankylosing spondylitis and plaque psoriasis in adults. Objective: This study investigated the pharmacokinetics (PKs), pharmacodynamics (PDs) safety, tolerability, and immunogenicity of single ascending subcutaneous injections of QX002N in healthy Chinese volunteers. Methods: A total of 65 healthy subjects were enrolled in a randomized, double-blind, placebo-controlled, single ascending dose phase I study (10-320 mg). Ten subjects were allocated to each cohort (containing 8 subjects treated with QX002N and 2 with placebo), except cohort 1 (only 4 subjects treated with QX002N and 1 with placebo). The studies on PKs, PDs, tolerability, and immunogenicity of QX002N were performed. Results: Our study showed that QX002N injection was well tolerated, without deaths, serious adverse events, or discontinuations due to treatment-emergent adverse events (TEAEs). Neither more frequency nor high severity of the drug-related adverse reaction was observed with increasing QX002N dose. The TEAEs in all subjects were considered Grades 1-2 (CTCAE 5.0) except for one case of Grade 3 (hypertriglyceridemia). Tmax of QX002N was obtained from 168 to 240 h across the dose range after administration. The Cmax and area under the curve of QX002N increased in proportion to dose, and showed linear PKs. Anti-drug antibody positivity was detected in one (1.9%) subject after drug administration. Conclusion: QX002N was well tolerated in our study. Based on the PKs and safety results of QX002N, 80 mg is recommended as the effective dose for a future phase Ib study. Clinical Trial Registration: https://www.chinadrugtrials.org.cn/, identifier ChiCTR1900023040.

Keywords: IL-17; QX002N; immunogenicity; pharmacokinetics; tolerability.

PubMed Disclaimer

Conflict of interest statement

Author MF was employed by the company Qyuns Therapeutics Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Mean concentration–time curve with standard deviation after subcutaneous injection of a single ascending dose of QX002N in healthy Chinese volunteers.
See this image and copyright information in PMC

References

    1. Australian Government Department of Health Therapeutic Goods Administration (TGA) (2021). TGA operations over the holiday period 2021-22. Available from: https://www.tga.gov.au/
    1. Blauvelt A. (2016). Ixekizumab: a New anti-IL-17A Monoclonal Antibody Therapy for Moderate-To Severe Plaque Psoriasis. Expert Opin. Biol. Ther. 16 (2), 255–263. 10.1517/14712598.2016.1132695 - DOI - PubMed
    1. Blauvelt A. (2008). T-helper 17 Cells in Psoriatic Plaques and Additional Genetic Links between IL-23 and Psoriasis. J. Invest. Dermatol. 128 (5), 1064–1067. 10.1038/jid.2008.85 - DOI - PMC - PubMed
    1. Bruin G., Hockey H. P., La Stella P., Sigurgeirsson B., Fu R., Patekar M., et al. (2020). Comparison of Pharmacokinetics, Safety and Tolerability of Secukinumab Administered Subcutaneously Using Different Delivery Systems in Healthy Volunteers and in Psoriasis Patients. Br. J. Clin. Pharmacol. 86 (2), 338–351. 10.1111/bcp.14155 - DOI - PMC - PubMed
    1. Chyuan I. T., Chen J. Y. (2018). Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies. Mediators Inflamm. 2018, 2403935. 10.1155/2018/2403935 - DOI - PMC - PubMed